Table 1. Clinicopathologic characteristics of patients grouped by type of BMI.
| Chararacteristics | noBMI | conBMI | disBMI | P-value | ||
|---|---|---|---|---|---|---|
| (n = 57) | (n = 19) | (n = 6) | ||||
| No. (%) | No. (%) | No. (%) | ||||
| noBMI vs conBMI | noBMI vs disBMI | conBMI vs disBMI | ||||
| Age at relapse (years) | ||||||
| Median (Range) | 59 (23–75) | 56 (36–71) | 58 (51–65) | 0.81 | 0.83 | 0.69 |
| Sex | 0.381 | 0.041 | 0.199 | |||
| Male | 42 (73.7) | 12 (63.2) | 2 (33.3) | |||
| Female | 15 (26.3) | 7 (36.8) | 4 (66.7) | |||
| saaIPI ≥2 | 37 (64.9) | 16 (84.2) | 5 (83.3) | 0.113 | 0.363 | 0.959 |
| Bulky mass ≥7.5 cm | 21 (36.8) | 4 (21.1) | 2 (33.3) | 0.205 | 0.865 | 0.539 |
| Duration of first complete remission <12 months* | 41 (71.9) | 11 (57.9) | 2 (33) | 0.254 | 0.053 | 0.294 |
| TRIL | 11 (19.3) | 5 (26.3) | 6 (100) | 0.516 | <0.001 | 0.002 |
| secondary CNS involvement | 12 (17.5) | 1 (5.3) | 0 (0) | 0.113 | 0.212 | 0.566 |
| prior Rituximab treatment | 44 (77.2) | 11 (57.9) | 4 (66.7) | 0.103 | 0.565 | 0.702 |
| failure to 1st salvage regimen | 22 (38.6) | 5 (26.3) | 3 (50) | 0.333 | 0.587 | 0.278 |
| completed SCT | 43 (75.4) | 14 (73.7) | 4 (66.7) | 0.878 | 0.639 | 0.739 |
| autologous SCT | 39 (68.4) | 11 (57.9) | 3 (50) | |||
| allogeneic SCT | 2 (3.5) | 0 (0) | 2 (33.3) | |||
| tandem SCT | 2 (3.5) | 1 (15.3) | 1 (16.7) | |||
| no CR before SCT | 27 (62.8) | 8 (57.1) | 4 (100)** | 0.706 | 0.133 | 0.109 |
| no CR after SCT | 17 (40.5) | 6 (42.9) | 2 (50) | 0.875 | 0.712 | 0.8 |
| COO (IHC) | 0.01 | 0.06 | 0.43 | |||
| GCB | 17 (56.7) | 3 (17.6) | 0 (0) | |||
| nonGCB | 13 (43.3) | 14 (82.4) | 3 (100) | |||
| unknown | 27 | 2 | 3 | |||
| p53 expression (IHC) | 0.088 | 0.184 | 0.859 | |||
| p53 wt | 15 (71.4) | 8 (44.4) | 2 (40) | |||
| p53 alteration | 6 (28.6) | 10 (55.6) | 3 (60) | |||
| unknown | 36 | 1 | 1 | |||
Abbreviations: BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, conBMI: concordant bone marrow infiltration, disBMI: discordant bone marrow infiltration, saaIPI: secondary age adjusted International Prognostic Index, TRIL: transformed indolent lymphoma, CNS: central nervous system, SCT: stem cell transplantation, CR: complete remission, COO: cell of origin, IHC: immunohistochemistry, GCB: germinal center B-cell, wt: wildtype
*including patients not achieving complete response after front-line treatment
**2 (50%) no response of indolent component, 2 (50%) no response of aggressive component.